PubMed Health⌕ Search

PubMed · 14692771

Beta-octafluorocorroles.

Abstract

The one-pot corrole synthesis first reported by the Gross and Paolesse groups appears to have evolved into a remarkably general and predictable self-assembly based synthetic reaction. Gross's solvent-free procedure (refs 8 and 9) has proven particularly effective in our hands and, in fact, more general than originally claimed. In earlier work (ref 17), we showed that the reaction works for a variety of aromatic aldehyde starting materials and was not limited to relatively electron-deficient aldehydes, as reported by Gross and co-workers. Here, we show that the pyrrole component is also variable in that 3,4-difluoropyrrole undergoes oxidative condensation with four different p-X-substituted benzaldehydes to yield the corresponding beta-octafluoro-meso-tris(para-X-phenyl)corroles (X = CF3, H, CH3, and OCH3). Further, we have prepared the Cu and FeCl derivatives of the beta-octafluorocorrole ligands. The XPS nitrogen 1s ionization potentials of these fluorinated ligands are some 0.7 eV higher than those of the corresponding beta-unfluorinated ligands. The oxidation half-wave potentials of the Cu and FeCl complexes of the fluorinated corroles are also positively shifted by 300-400 mV relative to their beta-unsubstituted analogues, demonstrating the strongly electron-deficient character of the fluorinated ligands. 1H NMR spectroscopy suggests that like their beta-unfluorinated counterparts, the new beta-octafluorinated triarylcorroles act as substantially noninnocent ligands, i.e., exhibit corrole pi-cation radical character, in the FeCl complexes. Quantitatively, however, NMR spectroscopy and DFT calculations indicate that the beta-octafluorinated corroles are somewhat less noninnocent (i.e., carry less radical character) than their beta-unfluorinated counterparts in the FeCl complexes. Temperature-dependent 19F NMR spectroscopy suggests that the Cu octafluorocorroles have a thermally accessible paramagnetic excited state, which we assign as a Cu(II) corrole pi-cation radical. We have previously reported that the electronic absorption spectra, particularly the Soret absorption maxima, of high-valent transition metal triarylcorroles are very sensitive to the nature of the substituents in the meso positions. In contrast, the Soret absorption maxima of free-base triarylcorroles are not particularly sensitive to the nature of the meso substituents. This scenario also holds for the fluorinated corroles described here. Thus, although the four free-base fluorinated triarylcorroles exhibit practically identical Soret absorption maxima, the Soret bands of the Cu derivatives of the same corroles red-shift by approximately 35 nm on going from the p-CF3 to the p-OCH3 derivative.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Erik Steene, Abhishek Dey, Abhik Ghosh. 2003-12-31. Beta-octafluorocorroles.. https://doi.org/10.1021/ja021158h

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗